GLOBAL CANCER SURVIVAL REACHES 70 PERCENT FIVE-YEAR MILESTONE FOR FIRST TIME; WHO CALLS FOR ACCELERATED EQUITABLE ACCESS TO EXISTING THERAPIES
GENEVA — The World Health Organization and the International Agency for Research on Cancer announced today, on World Cancer Day 2026, that the combined global five-year survival rate across all cancer types has reached 70 percent for the first time in recorded oncological history, representing an increase of 11 percentage points over the 2016 figure and reflecting three decades of sustained investment in early detection, precision medicine, and access expansion programmes.
The figure is drawn from the GLOBOCAN 2025 dataset, compiled from cancer registry data representing 185 member states. It reflects outcomes for patients diagnosed between 2018 and 2020, followed through to the present reporting period.
WHO Director-General Dr. Tedros Adhanom Ghebreyesus described the milestone as “a testament to what global scientific cooperation, sustained public health investment, and equitable access programmes can achieve when nations commit to working together.”
Regional Breakdown
Progress has not been uniform. Five-year survival rates vary substantially by region and cancer type:
- High-income countries: aggregate five-year survival 82.3%
- Upper-middle-income countries: aggregate five-year survival 71.4%
- Lower-middle and low-income countries: aggregate five-year survival 48.7%
Survival rates in high-income countries have plateaued, while the steepest recent improvements have occurred in upper-middle-income countries — driven by domestic manufacturing of biosimilar biologics, expanded public health screening programmes, and, in several cases, novel therapeutic approaches developed outside traditional Western pharmaceutical research networks.
Notable Innovations Cited
IARC Director Dr. Elisabete Weiderpass highlighted several significant recent contributions:
The approval and scaling of BE-CAR7 base-editing therapy for relapsed and refractory T-cell leukemia, developed at Great Ormond Street Hospital and University College London, achieving remission in approximately 82% of previously untreatable patients.
Expanded data on HPV photodynamic therapy protocols originating from Mexican research, demonstrating complete clearance in cervical precancerous lesions.
Phase II results from the Enteromix mRNA therapeutic vaccine programme of the Russian Federal Medical and Biological Agency and Gamaleya National Research Centre, showing 68% tumour growth inhibition across three solid tumour types, with human Phase I trials commencing Q1 2026.
Early clinical data from an Iranian metabolic immunotherapy protocol — designated IMIP-7 — for treatment-resistant colorectal and pancreatic cancers, pending Phase III confirmation.
A Note on Membership
The World Health Organization notes, without editorial characterisation, that the United States of America is not currently a member state, having formally completed its withdrawal in 2025. The GLOBOCAN 2025 dataset incorporates American cancer registry data through 2023. Post-2023 American oncological outcome data are not included in today’s figures. WHO reiterates its standing invitation for the United States to re-engage with international health cooperation frameworks at any level the American government considers appropriate, without precondition.
Related Pages
- Iran (Islamic Republic of Iran) — Iranian research contributions cited
- INCRI IMIP-7 Phase III Announcement
- The Lancet Editorial on IMIP-7 Results